The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk for failing to properly investigate and report adverse events related to Ozempic and Wegovy. If you’ve suffered harm from these medications, you may have legal options, and a mass tort lawyer can help you understand whether the manufacturer’s reporting failures strengthen your claim.
Table of Contents
Call Ankin Law at 312-600-0000 for a free consultation about your legal options.
Key Takeaways:
- The FDA found Novo Nordisk failed to properly investigate and report serious adverse events, including three deaths among semaglutide patients
- The pharmaceutical company violated federal requirements to submit some safety reports for serious and unexpected adverse events
- Patients who suffered complications from these drugs may have stronger legal claims due to the company’s reporting failures
- Illinois residents affected by Ozempic or Wegovy side effects may pursue compensation through mass tort litigation
Novo Nordisk Accused of Hiding Critical Safety Data
The FDA issued a warning letter to Novo Nordisk after discovering the pharmaceutical company systematically failed to investigate and report serious adverse events tied to its blockbuster diabetes and weight-loss drugs. According to the FDA’s findings, Novo Nordisk violated federal reporting requirements for Ozempic and Wegovy, including failures to properly document three deaths among patients taking semaglutide.
This isn’t a paperwork problem. The FDA’s warning letter makes clear that Novo Nordisk had information about serious adverse events but failed to meet its legal obligation to investigate and report them within mandated timeframes, some as short as 15 days for the most serious cases. For Chicago-area patients who developed gastroparesis, bowel obstructions, or other serious complications after taking these medications, this revelation raises questions about what the company knew, when they knew it, and whether they prioritized profits over patient safety.
What the FDA Investigation Revealed About Safety Reporting Failures
The FDA’s inspection of Novo Nordisk’s Plainsboro, New Jersey, facility, conducted between January 13 and February 7, 2025, uncovered a pattern of non-compliance that went beyond isolated mistakes. The agency found that the company failed to submit required 15-day safety reports for serious and unexpected adverse drug experiences.
According to the warning letter, the unreported cases included three deaths among patients taking semaglutide, one of which was a suicide. Another case involved a patient who reported suicidal ideation while taking the medication. The FDA explicitly noted that it did not conclude these deaths were necessarily caused by the medication, but rather that Novo Nordisk failed to properly investigate and report them as required by law.
The FDA also discovered that Novo Nordisk’s written procedures allowed adverse event reports to be rejected if a reporter believed the event was unrelated to the product, a standard inconsistent with federal regulations. The law requires reporting of any adverse event associated with a drug’s use in humans, regardless of perceived causation. The agency also found that Novo Nordisk’s procedures improperly required obtaining consent from reporters before conducting follow-up investigations, resulting in serious cases, including at least one patient death, going uninvestigated and unreported.
Legal Liability When Pharmaceutical Companies Fail to Report Adverse Events
Drug manufacturers have a legal duty to monitor their products and report safety problems to the FDA. When they fail to do this, and patients suffer harm as a result, they can be held accountable. A mass tort lawyer can help injured patients build a case based on several legal theories.
First, failure to warn. If Novo Nordisk knew or should have known about serious side effects but failed to adequately warn doctors and patients, the company may be liable for injuries that resulted. The FDA’s warning letter provides documented evidence that the company was aware of adverse events but did not properly process and report them.
Second, negligence in post-market surveillance. Pharmaceutical companies have ongoing responsibilities to track how their drugs perform in the real world and act on safety signals. Systematic failure to investigate and report adverse events could constitute negligence.
For Chicago residents who developed gastroparesis, gallbladder disease, bowel obstructions, or other serious complications after taking Ozempic or Wegovy, this FDA warning changes the landscape. Chicago product liability claims often turn on what the manufacturer knew and when they knew it. This warning letter provides a roadmap.
How This Affects Patients Who’ve Suffered Harm
If you took Ozempic or Wegovy and experienced severe gastrointestinal problems, you need to understand what this FDA action means for you. Many patients across Illinois developed conditions like gastroparesis, severe vomiting, intestinal blockages, and gallbladder disease after starting these medications. Some required hospitalization. Others needed surgery. Some still can’t eat normally months or years later.
Existing Ozempic lawsuits are already proceeding in courts across the country. However, the challenge many of these patients faced was proving that the manufacturer should have warned them about these risks. Now we know that Novo Nordisk had systematic failures in its adverse event reporting system, failed to investigate serious cases within required timeframes, and improperly invalidated reports that should have been submitted to the FDA.
The complications from these weight-loss drugs don’t always appear immediately. Some patients develop problems months after starting treatment. If you’re dealing with ongoing gastrointestinal problems that started after you began taking one of these drugs, you may have legal options even if you stopped taking it some time ago.
What to Do If You’ve Been Harmed
Document everything. If you experienced serious side effects from Ozempic or Wegovy, gather your medical records showing when you started the medication, what symptoms you developed, and how doctors treated your complications. Keep prescription records, hospital bills, and any documentation of how these health problems have affected your work and daily life.
Talk to a mass tort lawyer who handles pharmaceutical injury cases. These cases are complex and require attorneys who understand how to take on major pharmaceutical companies. A Chicago class action lawyer can evaluate whether you have a viable claim and explain how the FDA’s recent warning might strengthen your case.
If you or someone you love suffered serious complications after taking Ozempic or Wegovy, Ankin Law can help. Our legal team understands how to hold pharmaceutical companies accountable when they put profits ahead of patient safety. Call us at 312-600-0000for a free consultation, or visit our office in Chicago to discuss your case.
